The FCF Healthcare & Life Sciences Venture Capital Monitor – Europe is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies, displaying Venture capital financing trends in the European Life Sciences industry.
As of the end of October 2023 we identify the following current VC trends in Europe:
- In 2023, overall Life Sciences funding has reached EUR 7,324m
- Biotech received 42% of the total investment volume (-3% compared to the previous month)
- Oncology dominates as the top indication in Biotech
- AgomAb Therapeutics (Belgium) has the highest transaction volume of EUR 94m in October, followed by MinervaX (Denmark) EUR 54m and AstronauTx (United Kingdom) EUR 54m
- The EIC Fund (vehicle of the European Innovation Council, Belgium) dominates the Top 5 Investors (by deal volume), followed by Revival Healthcare Capital (United States) and Gilde Healthcare Partners (Netherlands)
- Top 5 Deals exceed EUR 130m each, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom)
Capital Markets Research
We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:
Venture Capital
Licensing
Healthcare & Life Sciences Venture Capital Monitor – Europe
Monthly Venture capital activities in the European Life Sciences sector
Biotech Venture Capital Monitor – USAMonthly Venture capital activities in the US Life Sciences sector
Life Sciences Venture Capital ReportRecent Venture capital trends in the European Life Sciences sector
Other Research
Life Sciences IPO ReportRecent IPO trends in the Life Sciences sector
Biotech Public Equity MonitorRecent valuations of listed European Life Sciences companies
MedTech & Diagnostics Public Equity MonitorRecent valuations of listed MedTech companies
Life Sciences SPAC MonitorPerformance overview of merged Life Sciences SPACs
NEWS
FCF Biotech Venture Capital Monitor – USA 10/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 10/2023”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 10/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 10/2023”. The Monitor is a monthly published overview of venture capital trends in the European
Munich-based Financing Specialist FCF Fox Corporate Finance advises Dutch Agricultural Technology Innovator In Ovo in a pivotal funding round of EUR 40 Million.
PRESS RELEASE Munich-based Financing Specialist FCF Fox Corporate Finance advises Dutch Agricultural Technology Innovator In Ovo in a pivotal funding round of EUR 40 Million. Munich, November 6, 2023 – FCF Fox Corporate Finance, a
FCF Biotech Venture Capital Monitor – USA 09/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 09/2023”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 09/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 09/2023”. The Monitor is a monthly published overview of venture capital trends in the European
